Company Description
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Country | Switzerland |
| Founded | 1895 |
| IPO Date | Nov 18, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 76,057 |
| CEO | Dr. Vasant Narasimhan M.D. |
Contact Details
Address: Lichtstrasse 35 Basel, V8 CH 4056 Switzerland | |
| Phone | 01141613241111 |
| Website | novartis.com |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer |
| Harry Kirsch | Chief Financial Officer |
| Victor Bulto | President of US |
| Dr. Patrick Horber M.D. | President of International |
| Dr. Steffen Lang Ph.D. | President of Operations |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Dr. Samir Shah M.D. | Global Head of Investor Relations |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk and Compliance Officer |
| Karen L. Hale | Chief Legal Officer |
| Dr. Robert Kowalski Pharm.D. | Chief People and Organization Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 2, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | 6-K | Report of foreign issuer |
| Jan 31, 2024 | 6-K | Report of foreign issuer |
| Jan 31, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Jan 31, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Jan 8, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2023 | 6-K | Report of foreign issuer |
| Dec 6, 2023 | 6-K | Report of foreign issuer |
| Nov 28, 2023 | 6-K | Report of foreign issuer |